A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

(Reuters) -European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S.

The iPhone maker's shares [rallied for a second day]( ...

Chugai Pharmaceutical Co. shares tumbled the most since 1977 after late-stage trial data on an obesity drug it licensed to ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...